TAURIGA SCIENCES, INC.
TAURIGA SCIENCES, INC. (TAUG): 1 pipeline candidate · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
D/E -3.17 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for TAURIGA SCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7K
Quarterly Burn
$262K
Runway
5.3 mo
Revenue
$103K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| tauri-gum | Preclinical |
Frequently asked questions
How many drug candidates are in TAURIGA SCIENCES, INC.'s pipeline?
TAURIGA SCIENCES, INC. (TAUG) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is TAURIGA SCIENCES, INC.'s lead drug candidate?
TAURIGA SCIENCES, INC.'s most advanced tracked candidate is tauri-gum (Preclinical) for nausea regulation in patients subjected to ongoing chemotherapy treatment.
What is TAURIGA SCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TAURIGA SCIENCES, INC. has approximately 5.3 months of cash runway.
Who is the CEO of TAURIGA SCIENCES, INC.?
Seth M. Shaw is the chief executive officer of TAURIGA SCIENCES, INC. (TAUG).
Get the full picture on TAURIGA SCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.